Lack of access to effective treatments is forcing blood cancer patients to take desperate measures 12 April 2018 Lack of funded access to...
Myeloma NZ
A Step Toward Precision Medicine
The IMF is very pleased to have established a partnership with AbbVie to conduct the largest, most comprehensive chart-review study of myeloma...
Multiple Myeloma Action Month March 2018
Multiple Myeloma action month March 2018: Thanks to medical innovation, Multiple Myeloma patients are living longer than ever before. Multiple...
Watch: What’s New in Myeloma Treatment: a New Zealand PerspectiveÂ
What’s New in Myeloma Treatment: a New Zealand Perspective Dr. Leanne Berkahn, Dr. Henry Chan, Dr. Phillip Insull, and Dr. David Simpson, spoke at...
Watch: Improving Survival in Multiple Myeloma
Improving Survival in Multiple Myeloma Dr. Henry Chan from North Shore Hospital spoke at our patient seminar on his recent work looking at multiple...
Research Review: Multiple Myeloma – Issue 25
Issue 25 of Multiple Myeloma Research Review. Highlights include: Induction VCD. Prediction of outcome in newly diagnosed myeloma Final...
Cancer Society calls for major changes to save lives
The Cancer Society is calling for major changes to cancer services to save lives. It says 2,500 more New Zealanders would have survived cancer if...
Newsletter: February 2018
Happy New Year & greetings to you all Patient seminars: save the date Auckland on 28 February at North Shore Hospital Auditorium Wellington on 8...
You’re invited to a patient seminar – Wellington
INVITATION Patient Seminar: CAR T-Cell Therapy: a New Frontier in Blood Cancer Treatment Presented by Dr Rob Weinkove on 8 March, 5.30-7pm at...
You’re invited to a patient seminar – Auckland
INVITATION Patient Seminar: What's New in Myeloma Treatment: a New Zealand Perspective with...
Multinational Clinical Study
Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory...
Research Review: Multiple Myeloma – Issue 24
Issue 24 of Multiple Myeloma Research Review. Highlights include: Is MRD the best predictor of response? ctDNA and risk of distant relapse....






